Empty Capsules Market to Expand at a Cagr of 7.3%, by 2026
- Submitted by: yogesh1
- Views: 99
- Category: Other
- Date Submitted: 06/28/2016 07:25 AM
- Pages: 3
- Report this Essay
Steady increase in the number of photochemically unstable drugs will continue to positively influence the growth of the empty capsules market in 2016, with global revenues expected to increase by 6% to reach US$ 1,432.6 Mn.
Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers.
Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016. Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively.
Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-782
Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market.
Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$...
Increasing demand for vegan and Halal pharmaceuticals is ramping up adoption, and providing support to a market, which is primarily driven by Type-A (pork-based) capsules. Development of hypromellose capsules for the treatment of pulmonary and non-pulmonary diseases are also creating growth opportunities for manufacturers.
Gelatin-based capsules will continue to account for higher demand than vegetarian-based capsules, accounting for nearly 71% revenue share of the market in 2016. Type-A (pork skin), the largest segment in terms of raw materials, will grow at a lower rate than non-pork based empty capsules, especially hydroxy propyl methyl cellulose (HPMC) and fish bone gelatin. While type-A (pork skin) revenues will grow by 4.62% in 2016, fish bone gelatin and HPMC revenues will grow by 8.87% and 8.40% respectively.
Size “4” capsules will continue to be the largest revenue segment on the basis of capsule size, with total revenues expected to reach US$ 263.1 Mn in 2016. Size “1” and Size “2” capsules will also account for substantial demand, collectively accounting for over US$ 430 Mn in market revenues in 2016.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-782
Empty capsules are administered orally, and only a small percentage of these drugs is inhaled – the former accounted for 91.1% revenue share of the global market in 2015. While inhalation-based empty capsules will grow at a higher rate, they will continue to account for a revenue share of less than 10% of the overall market.
Pharmaceutical companies – the largest end-use segment for empty capsules – will continue to post strong gains in 2016. Revenues from this segment are anticipated to increase at 5.79% in 2016 to total US$...